Organon CEO Kevin Ali Resigns After Contraceptive Sales Probe
Photo by Markus Winkler on Unsplash
Organon's CEO, Kevin Ali, is stepping down after an internal investigation uncovered improper sales practices involving Nexplanon, where personnel allegedly urged U.S. wholesalers to buy excessive amounts to meet revenue targets. The Head of U.S. Commercial & Government Affairs was also terminated, and Ali forfeited severance and retirement benefits, with Joseph Morrissey appointed as interim CEO.
Key takeaways
- Organon CEO Kevin Ali is resigning following an internal investigation into improper sales practices related to the Nexplanon contraceptive implant, the company announced Monday
- The investigation revealed that Organon personnel requested certain U
- wholesalers to purchase excessive amounts of Nexplanon at the end of multiple quarters, allegedly to meet revenue forecasts and external expectations
Related Topics
Want coverage like this for your company?
Local & industry wins build trusted proof, SEO/geo signals and prime national editors.
Verified mention available
Is this your company?
Set up real-time alerts and keep your Heartspace News coverage accurate. Verified teams can update profiles, request corrections, and collaborate on future stories.
Want to turn mentions into momentum? Find your best path with the Fit Checker. Verified profiles receive a free consult.